Apollomics Net Income From Continuing Ops from 2010 to 2026
| APLM Stock | 18.30 0.38 2.12% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -48.5 M | Current Value -50.9 M | Quarterly Volatility 47.8 M |
Check Apollomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apollomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.6 K, Interest Expense of 114.2 K or Gross Profit of 216.3 K, as well as many indicators such as Price To Sales Ratio of 49.84, Dividend Yield of 0.0 or PTB Ratio of 1.75. Apollomics financial statements analysis is a perfect complement when working with Apollomics Valuation or Volatility modules.
Apollomics | Net Income From Continuing Ops | Build AI portfolio with Apollomics Stock |
Evaluating Apollomics's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Apollomics Class A's fundamental strength.
Latest Apollomics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Apollomics Class A over the last few years. It is Apollomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Apollomics Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (87,320,883) | |
| Coefficient Of Variation | (54.74) | |
| Mean Deviation | 28,970,159 | |
| Median | (74,820,000) | |
| Standard Deviation | 47,803,354 | |
| Sample Variance | 2285.2T | |
| Range | 192.3M | |
| R-Value | (0.18) | |
| Mean Square Error | 2354.9T | |
| R-Squared | 0.03 | |
| Significance | 0.48 | |
| Slope | (1,743,137) | |
| Total Sum of Squares | 36562.6T |
Apollomics Net Income From Continuing Ops History
About Apollomics Financial Statements
Apollomics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Apollomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.5 M | -50.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Apollomics Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.